FindTrial
Sign In

Post-Marketing Study of FOLFIRI Therapy + Avastin (Bevacizumab) in Patients with Metastatic Colorectal Cancer

Post-Marketing Study of FOLFIRI Therapy + Avastin (Bevacizumab) in Patients with Metastatic Colorectal Cancer

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220517
Enrollment
Unknown
Registered
2008-02-01
Start date
2008-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

first-line metastatic colorectal cancer.

Interventions

investigational material(s) Generic name etc : Avastin INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: the first-line therapy of metastatic colorectal cancer, age >=20 yrs old, PS=0-1, etc.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Response rate, safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026